Replies to post #3312 on Delcath Systems Inc (DCTH)

[ash111]

As a result, Delcath believes it has sufficient capital to fund its operating activities through the end of 2017. 

Expanded the FOCUS Phase 3 Trial in hepatic dominant ocular melanoma to include 10 new research centers in the U.S. and Europe; 

Negotiations by hospitals in Germany to determine reimbursement levels for CHEMOSAT under the ZE national system are expected to conclude during our fourth quarter.

In Europe, our system has been commercially available since 2012 

$4m cap a/o today on more solid balance sheet due $35m founding round closed on June 2016.
Nice Beats also reduced costs and net lose decreased by 70%.